{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:12:39Z","timestamp":1790691159199,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.4765","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T15:10:26Z","timestamp":1559920226000},"page":"e194765","source":"Crossref","is-referenced-by-count":45,"title":["Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C"],"prefix":"10.1001","volume":"2","author":[{"given":"Elizabeth A.","family":"McGlynn","sequence":"first","affiliation":[{"name":"Kaiser Permanente Research, Kaiser Permanente, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Adams","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Effectiveness and Safety Research, Kaiser Permanente, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kramer","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Effectiveness and Safety Research, Kaiser Permanente, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep K.","family":"Sahota","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Transplant Hepatology, Southern California Permanente Medical Group, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shenkman","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes & Biomedical Informatics, University of Florida College of Medicine, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida College of Medicine, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"issue":"3","key":"zoi190200r1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.v69.3","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"zoi190200r2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/liv.2018.38.issue-2","article-title":"Changing trends in complications of chronic hepatitis C.","volume":"38","author":"Lu","year":"2018","journal-title":"Liver Int"},{"issue":"2","key":"zoi190200r3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection.","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci"},{"issue":"13","key":"zoi190200r4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"9286","key":"zoi190200r5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"zoi190200r6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi190200r7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/hep.23429","article-title":"Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.","volume":"51","author":"Feuerstadt","year":"2010","journal-title":"Hepatology"},{"key":"zoi190200r8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijid.2016.12.023","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: a meta-analysis.","volume":"55","author":"Tao","year":"2017","journal-title":"Int J Infect Dis"},{"key":"zoi190200r9","first-page":"CD012143","article-title":"Direct-acting antivirals for chronic hepatitis C.","volume":"9","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"zoi190200r10","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi190200r11","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi190200r12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi190200r13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40121-016-0118-x","article-title":"Desirable characteristics of hepatitis C treatment regimens: a review of what we have and what we need.","volume":"5","author":"Bidell","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"4","key":"zoi190200r17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/amiajnl-2014-002747","article-title":"Launching PCORnet, a national patient-centered clinical research network.","volume":"21","author":"Fleurence","year":"2014","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"zoi190200r18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi190200r21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"zoi190200r22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/jlts.2003.50009","article-title":"Longitudinal assessment of mortality risk among candidates for liver transplantation.","volume":"9","author":"Merion","year":"2003","journal-title":"Liver Transpl"},{"issue":"2","key":"zoi190200r23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?","volume":"61","author":"Di Bisceglie","year":"2015","journal-title":"Hepatology"},{"issue":"10","key":"zoi190200r24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/MCG.0000000000000986","article-title":"Risk of hepatitis B virus reactivation among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection.","volume":"52","author":"Yanny","year":"2018","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"zoi190200r25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cld.426","article-title":"Defining and grading HBV reactivation.","volume":"5","author":"Visram","year":"2015","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"2","key":"zoi190200r26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"issue":"11","key":"zoi190200r27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"5","key":"zoi190200r28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"12","key":"zoi190200r29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study.","volume":"9","author":"D\u2019Agostino","year":"1990","journal-title":"Stat Med"},{"issue":"3","key":"zoi190200r30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"zoi190200r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.24082","article-title":"The value of observational research in liver diseases.","volume":"53","author":"Lindor","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"zoi190200r32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"zoi190200r33","first-page":"S0168-8278(17)32273-0","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.","author":"Ioannou","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"zoi190200r34","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"zoi190200r14","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm522932.htm. Published October 4, 2016. Accessed November 25, 2018."},{"key":"zoi190200r15","unstructured":"Institute for Safe Medication Practices. QuarterWatch Reports. New data from 2016 Q2. http:\/\/www.ismp.org\/quarterwatch\/pdfs\/2016Q2.pdf. Published 2017. Accessed November 25, 2018."},{"key":"zoi190200r16","unstructured":"US Food and Drug Administration. FDA\u2019s Sentinel Initiative. https:\/\/www.fda.gov\/safety\/fdas-sentinel-initiative. Published 2018. Accessed May 5, 2019."},{"key":"zoi190200r19","unstructured":"Centers for Disease Control and Prevention; National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm. Published 2013. Accessed November 18, 2018."},{"key":"zoi190200r20","unstructured":"Centers for Disease Control and Prevention; National Center for Health Statistics. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). https:\/\/www.cdc.gov\/nchs\/icd\/icd10cm.htm. Published 2018. Accessed November 18, 2018."},{"key":"zoi190200r35","unstructured":"US Preventive Services Task Force. Final recommendation statement: hepatitis C: screening. https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/hepatitis-c-screening.Published 2016. Accessed November 18, 2018."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/6\/e194765\/17635216\/mcglynn_2019_oi_190200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T15:10:29Z","timestamp":1559920229000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.4765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.4765","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]}}}